Global Pulmonary Arterial Hypertension Market
Global Pulmonary Arterial Hypertension (PAH) market was valued at $5.0bn in 2015 and is forecast to grow at a modest 6.0% CAGR between 2015 and 2024, to result in 2024 global sales of $9.0bn.
PAH is broadly split into two classes, primary or secondary. Primary pulmonary hypertension (PPH) refers to pulmonary hypertension occurring without an identifiable cause. Secondary pulmonary arterial hypertension (PAH) occurs in association with some other identifiable medical condition.
Key players include Actelion Pharmaceuticals, Arena Pharmaceuticals, Bayer, Gilead Sciences, GSK, Merck, Pfizer, Reata Pharmaceuticals., SteadyMed, United Therapeutics, & Teva among others. The companies are focused on deals & alliances with a goal to expand the product portfolio. For instance, Actelion gained U.S. rights to Ventavis through its 2007 acquisition of CoTherix. Ventavis sales has been modest due to competition from Tyvaso, the second inhaled therapy for PAH. There are currently thirteen drugs indicated for the treatment of PAH in the U.S.